Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

SCRI Development Innovations

Status and phase: Enrolling; Phase 2

Conditions: Multiple Myeloma

Treatments: Drug: Teclistamab; Drug: Talquetamab; Drug: Tocilizumab

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT05972135

MM165

Details and patient eligibility

About

This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients

Full description

• This is a two-arm, non-randomized, multicenter, prospective study in adult patients with RRMM, who are administered Teclistamab (TECVAYLI™) or Talquetamab (TALVEY™), in the post-marketing setting.
• Teclistamab (TECVAYLI™) is a humanized IgG-4 PAA bispecific antibody designed to target the CD3 receptor complex on T cells and BCMA on B-lineage cells.
• Talquetamab (TALVEY™) is a humanized IgG-4 bispecific antibody designed to target the CD3 receptor complex on T cells and GPRC5D-expressing multiple myeloma (MM) cells This study will investigate the use of prophylactic tocilizumab to reduce the incidence and severity of CRS associated with teclistamab or talquetamab administration, to enable administration of the step-up dosing regimen of teclistamab or talquetamab in an outpatient setting.

Enrollment: 75 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Be ≥18 years of age (or the higher legal age in the jurisdiction in which the study is taking place) at the time of informed consent

• Has documented diagnosis of MM according to the IMWG diagnostic criteria (Rajkumar 2011).

• Has received 2 or more prior MM therapies including a PI, IMiD and CD38 antibody.

• Has an ECOG performance status (Oken 1982) of 0 to 1.

• Measurable disease at screening, as assessed by local laboratory, defined by any of the following:

  • Serum M-protein level ≥0.5 g/dL; or
  • Urine M-protein level ≥200 mg/24 hours; or
  • Light chain MM without measurable M-protein in the serum or the urine: serum free light chain (sFLC) ≥10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio.
  • For participants without measurable disease in the serum, urine, or involved FLC, presence of plasmacytomas (≥2 cm).

• Human immunodeficiency virus-positive participants are eligible if they meet all of the following:

  • No detectable viral load (i.e., <50 copies/mL) at screening
  • CD4+ count >300 cells/mm3 at screening
  • No acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within 6 months of screening
  • Receiving highly active antiretroviral therapy (HAART). Any changes in HAART due to resistance/progression should occur at least 3 months prior to enrollment. A change in HAART due to toxicity is allowed up to 4 weeks prior to enrollment.

• Adequate organ system function

• Body weight >35 kg.

• A participant of childbearing potential must have a negative highly sensitive serum (β-hCG) at screening and within 72 hours of the start of study treatment and must agree to further serum or urine pregnancy tests during the study.

• A participant must agree to abide by protocol defined contraceptive requirements for the duration of the study

• A participant must sign an ICF indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study.

• A participant is required to stay within 30 minutes of transportation to the site and remain in the company of a competent adult at all times until 48 hours following administration of all doses within the teclistamab or talquetamab step-up dosing schedule

• A participant must agree to carry the study participant identification wallet card at all times.

• A participant must comply with all the protocol requirement procedures, including measuring and recording of body temperature and blood oxygen saturation twice daily (≥8 hours apart) during the first 2 cycles of teclistamab or talquetamab treatment and coming to the study site for safety assessments.

• A participant and the accompanying competent adult must be made aware of the presenting sign sand symptoms of teclistamab- or talquetamab- associated toxicities, including but not limited to CRS, ICANS, infections, etc. The accompanying competent adult must watch the participant at all times for teclistamab- or talquetamab- associated toxicities, until 48 hours after the first treatment dose of teclistamab or talquetamab.

Exclusion criteria

• Has high tumor burden, defined as having ≥60% plasma cell infiltrate on the bone marrow biopsy or aspirate, whichever is higher, or with multiple extramedullary disease sites or plasmacytomas.

• Has a rapidly progressing disease per investigator assessment.

• Has plasma cell leukemia (>2.0×10^9/L plasma cells by standard differential), Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or primary amyloid light-chain amyloidosis.

• Has known active CNS involvement or exhibits clinical signs of meningeal involvement of MM.

• Has risk factors for developing clinically significant TLS and requiring management with increased hydration, allopurinol, or rasburicase.

• Has myelodysplastic syndrome or active malignancies (ie, progressing or requiring treatment change in the last 12 months) other than RRMM. The only allowed exceptions are:

  • Any malignancy that was not progressing nor requiring treatment change in the last 12 months.
  • Malignancies treated within the last 12 months and considered at very low risk for recurrence:
  • Non-muscle invasive bladder cancer (solitary Ta-PUNLMP or low grade, <3 cm, no CIS).
  • Skin cancer (non-melanoma or melanoma).
  • Noninvasive cervical cancer.
  • Breast cancer: adequately treated lobular carcinoma in situ or ductal carcinoma in situ, localized breast cancer and receiving antihormonal agents.
  • Localized prostate cancer (M0, N0) with a Gleason Score ≤7a, treated locally only (RP/RT/focal treatment).
  • Other malignancy that is considered at minimal risk of recurrence.

• Has Grade ≥3 hematologic AEs or Grade ≥3, clinically significant non-hematologic AEs.

• Has fever or active infection (bacterial, viral, or uncontrolled systemic fungal) at time of study enrollment.

• Has active autoimmune disease or a documented history of autoimmune disease with the exception of vitiligo, type I diabetes, and prior autoimmune thyroiditis that is currently euthyroid based on clinical symptoms and laboratory testing.

• Has clinically significant coagulopathy that would increase the risk of bleeding in the setting of cytopenia.

• Shows a deterioration in neurologic status, including mental status changes such as confusion or increased somnolence.

• Has psychiatric disorders (eg, alcohol or drug abuse), dementia, or altered mental status that would compromise the ability to provide informed consent or comply with the clinical protocol.

• History of stroke, transient ischemic attack or seizure within 6 months of signing ICF.

• Presence of the following cardiac conditions:

  • New York Heart Association stage III or IV congestive heart failure.
  • Myocardial infarction or CABG ≤6 months prior to enrollment.
  • History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration.
  • History of severe non-ischemic cardiomyopathy.
  • Poorly controlled coronary artery disease and/or congestive heart failure.
  • Uncontrolled cardiac arrhythmia or clinically significant ECG abnormalities.

• Has hepatitis B infection (ie, HBsAg or HBV-DNA positive). In the event the infection status is unclear, quantitative viral levels are necessary to determine the infection status.

• Has active hepatitis C infection as measured by positive HCV-RNA testing. Participants with a history of HCV antibody positivity must undergo HCV-RNA testing. If a participant with history of chronic hepatitis C infection (defined as both HCV antibody and HCV-RNA positive) completed antiviral therapy and has undetectable HCV-RNA 12 weeks following the completion of therapy, the participant is eligible for the study.

• Has COPD with FEV1 <50% of predicted.

• Has eGFR <20 ml/min or is dependent on dialysis.

• Has other medical issue that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site, to understand informed consent or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.

• For talquetamab arm only: Prior Grade 3 or higher CRS related to any T-cell redirection (e.g., CD-3 redirection technology or CAR-T cell therapy), or any prior GPRC5D-targeting therapy.

• Has received packed RBC or platelet transfusions within the last 7 days prior to dosing.

• Has contraindications to the use of tocilizumab or IVIG per local prescribing information.

• Has received live vaccine(s) within 1 month prior to screening or plans to receive live vaccines during the study.

• Has received live, attenuated vaccine within 30 days before the first dose of teclistamab or talquetamab. Live, attenuated influenza vaccines are permitted as late as 30 days before the study treatment.

• Has received an investigational intervention or used an invasive investigational medical device within 14 days before the planned first dose of study treatment or received an investigational biological product within 14 days or 5 half-lives, whichever is longer, before the planned study treatment, or is currently enrolled in an investigational study.

• History of antitumor therapy as follows, before the first dose of study drug:

  • Targeted therapy, epigenetic therapy, or treatment with an investigational drug or used an invasive investigational medical device within 21 days or at least 5 half-lives, whichever is less.
  • Monoclonal antibody treatment for MM within 21 days.
  • Cytotoxic therapy within 21 days.
  • PI therapy within 14 days.
  • Immunomodulatory agent therapy within 7 days.
  • For teclistamab arm only: Prior Ggene modified adoptive cell therapy (eg, chimeric antigen receptor modified [CAR]-T cells, NK cells) within 3 months. or BCMA therapy).
  • Radiotherapy within 14 days or focal radiation within 7 days.
  • For talquetamab arm only: Prior CAR-T or BCMAbispecific antibody therapy are allowed.

• History of stem cell transplant:

  • An allogeneic stem cell transplant within 6 months. Participants who received an allogeneic transplant must be off all immunosuppressive medications for ≥42 days without signs of graft-versus-host disease.
  • An autologous stem cell transplant ≤12 weeks before the first dose of study drug.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

75 participants in 2 patient groups

Teclistamab

Experimental group

Description:

Participants will receive step up dosing of Teclistamab following the recommended dosage of TECVAYLI™ USPI followed by weekly dosing for twelve 28-day cycles, until disease progression, unacceptable toxicity, or the EOT (end of Cycle 12). Teclistamab dosing may be reduced to once every 2 weeks for participants who achieve partial response (PR) or better after 6 months of therapy.

Treatment:

Drug: Tocilizumab

Drug: Teclistamab

Talquetamab

Experimental group

Description:

Participants will receive step up dosing of Talquetamab following the recommended dosage of TALVEY™ USPI followed by every 2 week dosing for six 28-day cycles, until disease progression, unacceptable toxicity, or the EOT (end of Cycle 6). Talquetamab dosing may be reduced to once every 4 weeks for participants who achieve very good partial response (VGPR) or better after Cycle 4

Treatment:

Drug: Tocilizumab

Drug: Talquetamab